PEMF for
Facet Joint Syndrome.

July 2026 · 9 min read · Clinical Protocol

What Is Facet Joint Syndrome?

The spine carries paired zygapophyseal (facet) joints — small synovial articulations at the back of each segment that guide movement and resist torsional forces. When these joints degenerate, inflame, or develop osteophytes, the result is facet joint syndrome (also called zygapophyseal arthropathy or facet arthritis). It is a mechanical, nociceptive pain — distinct from disc or nerve-root (radicular) pain.

Facet-mediated pain is estimated to account for a substantial share of chronic low back pain in adults over 40 (commonly cited clinical estimates put it around 15–40%), making it one of the most prevalent structural pain generators after non-specific muscle strain. Despite this, it is chronically undertreated: many patients receive a generic low-back protocol regardless of pain generator.

The most affected lumbar levels are L4–5 and L5–S1, the segments that bear the highest compressive and rotational loads in upright posture; the cervical facets are similarly affected in neck-dominant presentations. In the Philippines, prolonged sitting (a BPO workforce of roughly 1.3–1.5 million), heavy manual carrying (a large agricultural and construction workforce), and habitual asymmetric postures in transport work accelerate facet load.

How to Identify Facet-Mediated Pain

Facet joint pain has a recognizable clinical pattern distinct from disc herniation, stenosis, and sacroiliac pathology:

• Location: axial back or neck pain, often bilateral but asymmetric; referred pain to the buttock or posterior thigh, but rarely below the knee — a key distinction from radiculopathy
• Aggravating factors: extension, rotation and prolonged standing — all of which compress the facet joints; often worse first thing in the morning
• Relieving factors: forward flexion (sitting, bending forward), lying down with knees bent
• Clinical test: Kemp's test (extension-rotation provocation) supports a facet origin; absence of neurological deficit (normal straight-leg raise, intact reflexes, no dermatomal numbness) points away from radiculopathy
• Diagnostic confirmation: a medial branch nerve block giving ≥50% pain relief on two separate occasions remains the reference-standard diagnostic criterion

How PEMF Interacts with the Facet Joint

PEMF delivers short, low-intensity, non-thermal electromagnetic pulses that induce small currents at the cellular level. The mechanisms described in the literature include reduced local inflammatory signalling, improved microcirculation and venous-lymphatic return, and reduction of oedema around the joint capsule and surrounding soft tissue. Because facet pain is characterised by local inflammation, capsular oedema and irritation of the medial-branch nerve endings, PEMF is a rational adjunct aimed at lowering the pain-and-inflammation cycle so active rehabilitation can proceed. A review of PEMF in soft-tissue inflammation (Strauch et al. 2009, PubMed 19371845, Albert Einstein College of Medicine) supports the oedema-reduction and angiogenesis mechanism at the capsular level. One operational point matters here: the treatment needs no contact, pressure or manipulation of an irritable spine, so it can be applied to patients who do not yet tolerate manual therapy. It does not reverse structural wear — it supports symptom control alongside loading and motor-control work.

The Evidence — Stated Honestly

There is no dedicated randomized controlled trial of PEMF for facet joint syndrome specifically. The evidence is extrapolated from trials on joint and soft-tissue pain and on spinal osteoarthritis, and it should be presented to referring physicians that way. Overstating it is the fastest way to lose an orthopedic or pain-management referral channel.

The most relevant general evidence is the 2025 prospective multi-center randomized clinical trial (PMC11914662, n=91, five orthopedic clinics) in joint and soft-tissue pain: 36% pain reduction versus 10% with standard care (p<0.0001), and a 55% reduction in medication use versus 12%. This studied joint and soft-tissue pain in general — not facet joints specifically — so the transfer is at the tissue-mechanism level, not direct facet-specific proof.

In the spine itself, Trock et al. 1994 (PubMed 7837158) ran parallel randomized controlled trials in knee (n=86) and cervical spine osteoarthritis (n=81) — where the facet (zygapophyseal) joints are the degenerating joints — reporting statistically significant improvement in pain and function versus placebo, sustained at one-month follow-up. Together with the soft-tissue mechanism above, these form the honest evidence base: a rational adjunct with a plausible mechanism, not a facet-specific cure.

Who Is This Protocol For?

PEMF for facet joint syndrome is appropriate for:

• Patients with axial back or neck pain confirmed or clinically suspected to be facet-mediated (Kemp's positive, no radiculopathy, worse with extension/rotation)
• Patients who have had medial branch blocks but want a non-injection maintenance option
• Patients with multilevel facet degeneration where repeat injections carry a cumulative steroid burden
• Post-radiofrequency ablation patients (medial-branch nerves regenerate over 6–12 months; PEMF is used as a non-injection option during that window)
• Elderly patients with co-morbidities limiting NSAID use (renal, GI, cardiovascular risk)
• Manual and shift workers whose occupational demands prevent adequate rest — sessions can be scheduled around work

Clinical Protocol

1. Diagnosis and exclusion: history, extension/rotation provocation testing and para-spinal palpation. Red flags excluded and medical referral made where a serious cause is suspected.
2. Load management: workstation and posture correction, avoidance of sustained end-range extension, graded activity and scheduled movement breaks.
3. PEMF sessions: 30 minutes, 1–2 times per week (up to 3 in an acute phase, with a day between sessions), coils positioned over the affected lumbar or cervical segment with the patient prone or seated. Parameters — waveform, frequency and cycle duration — are selected by the system according to the chosen indication.
4. Active rehabilitation: core and deep-stabiliser strengthening, motor control, hip and thoracic mobility, and spinal mobilisation — the evidence-based cornerstone.
5. Adjunct therapy: manual therapy, dry needling or acupuncture per patient status and clinician judgment.
6. Reassessment every 2–4 weeks: pain intensity, provocation testing and function. No improvement means the diagnosis is revisited, not that the dose is increased.

• Course: a minimum of three sessions before judging response; many patients report a change within a few sessions, with fuller improvement over several weeks of combined treatment.
• Supervision required: none — the Hands-Free model lets a second patient be treated in parallel, without a therapist in the room during treatment.
• Session pricing (Philippines): typically ₱1,500–₱2,500 per session, within a broad indication basket.

PEMF vs. Conventional Facet Treatments

PEMF does not compete with these treatments — it complements them: a non-invasive, comfortable adjunct that can be applied before or after an intervention, over time, alongside the active rehabilitation that remains the cornerstone.

The Post-Injection and Post-RFA Patient Segment

One of the highest-value patient segments for a PEMF clinic in the Philippines is the post-injection facet patient — someone who has already had medial branch blocks, found relief, and is either awaiting RFA, unable to afford RFA, or in the nerve-regeneration window 6–12 months after RFA.

• Already diagnosed — the facet origin is confirmed, so no additional diagnostic workup is required
• Already motivated — they have paid for and tolerated injections
• Seeking a non-injection option — PEMF fits this gap as an adjunct, not a diagnostic replacement
• High course-completion rate — they understand the chronic nature of their condition

A referral relationship with a pain-management specialist performing medial branch blocks can be a steady source of appropriate, pre-diagnosed patients.

Regulatory Status

• FDA 510(k): the technology's clearance scope is pain and tissue oedema; dedicated bone-growth stimulators are additionally cleared for non-union and spinal fusion.
• CE marking: conformity with European medical device requirements.
• Israeli Ministry of Health (AMAR) registration.
• IEC 60601: international safety standard for electrical medical equipment.
• ICNIRP guidelines: safe electromagnetic exposure levels.

Contraindications

• Pacemaker or implantable cardioverter-defibrillator: absolute contraindication
• Pregnancy: absolute contraindication
• Active malignancy at the treatment site: absolute contraindication
• Metal implants or spinal fixation hardware near the field: relative — coil position dependent
• Epilepsy: relative — neurologist clearance required
• Red flags — fever, unexplained weight loss, progressive weakness or numbness, bladder/bowel changes, or pain after significant trauma — require medical evaluation first. PEMF is never a first response to undiagnosed spinal pain.

FAQ: Facet Syndrome & PEMF

Can PEMF replace medial branch injections?

For pain modulation, PEMF is a non-invasive option that avoids the steroid burden of injections. For diagnosis (confirming facet origin), medial branch blocks retain their reference-standard role. In practice PEMF is used as a maintenance adjunct after injection has confirmed the diagnosis — not as a diagnostic replacement.

How many sessions before improvement?

Most patients notice a change within a few sessions, but response varies. Evaluate after at least three sessions and track function and provocation-test pain over several weeks rather than a single day's reading.

Is this appropriate for elderly patients with multi-level facet degeneration?

Yes — PEMF has no upper age limit and suits elderly patients with polypharmacy concerns or renal/hepatic limits on NSAID use. The no-supervision model also makes it practical in outpatient settings.

Can PEMF slow facet joint degeneration over time?

No — this should not be claimed. PEMF is used for symptom control (pain and oedema), not structural reversal. There are no longitudinal facet-cartilage trials demonstrating disease modification, and it should be presented to patients and referrers strictly as a complementary treatment alongside active rehabilitation.

Positioning for Philippine Clinics

Chronic musculoskeletal pain is highly prevalent in the Philippines, and facet-mediated axial pain is a large share of it. The highest-risk occupational segments are the BPO and office workforce in sustained seated postures, manual and construction labour, agricultural workers, and transport/logistics workers. Because back and neck pain here is overwhelmingly self-managed with over-the-counter analgesics, a clinic has a clear, honest argument for a non-pharmacological adjunct. PainFree operates over 70 clinics across Israel with more than 25 years of experience, and identifies facet-mediated axial pain as one of its highest-volume PEMF indications alongside knee osteoarthritis and chronic low back pain.